ABLIVA AB
Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The portfolio includes projects at different stages and ranges from early discovery phase to clinical phase.
ABLIVA AB
Social Links:
Industry:
Biotechnology Clinical Trials Health Care
Founded:
2000-01-01
Address:
Lund, Skane Lan, Sweden
Country:
Sweden
Website Url:
http://www.abliva.com
Total Employee:
11+
Status:
Active
Contact:
+46 (0)46-275 62 20
Email Addresses:
[email protected]
Total Funding:
38.43 M USD
Technology used in webpage:
Google Maps Microsoft Azure DNS Google Maps API MediaElement.js
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Current Employees Featured
Founder
Stock Details
Investors List
IP Group
IP Group investment in Post-IPO Equity - Abliva AB
Nyenburgh Investment Partners
Nyenburgh Investment Partners investment in Post-IPO Equity - Abliva AB
U.S. Department of Defense
U.S. Department of Defense investment in Grant - Abliva AB
Congressionally Directed Medical Research Programs
Congressionally Directed Medical Research Programs investment in Grant - Abliva AB
Vinnova
Vinnova investment in Grant - Abliva AB
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2016-08-15 | Isomerase Therapeutics | Abliva AB investment in Funding Round - Isomerase Therapeutics | N/A |
Official Site Inspections
http://www.abliva.com Semrush global rank: 6.42 M Semrush visits lastest month: 1.03 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Abliva AB"
Abliva – Delivering mitochondrial health
Abliva develops medicines for the treatment of primary mitochondrial diseases.See details»
Abliva – Abliva
Abliva - MitoWorld
Abliva develops medicines for the treatment of mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell’s energy provider, the mitochondria, do not …See details»
Abliva AB - LinkedIn
Abliva AB | 2,461 followers on LinkedIn. Delivering mitochondrial health | Abliva discovers and develops medicines for the treatment of mitochondrial diseases.See details»
Abliva AB - Crunchbase Company Profile & Funding
Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly.See details»
Org Chart Abliva - The Official Board
Unfortunately, you don't own enough credit to see this new org chart. To continue, you can add a name in one of the org charts you recently viewed or test our Premium membership.See details»
ANNUAL REPORT 2021 - MFN
Abliva’s discovery projects focus on gaining a deeper understanding of the mechanisms underlying primary mitochondrial diseases in order to enable us to design new molecules and …See details»
Corporate Governance Report - Abliva
Abliva AB (publ) (Abliva or the Company) is a Swedish public limited company with corporate identity number 556595-6538. Abliva’s registered office is in the Municipality of Lund and the …See details»
Abliva AB, ABLI:STO profile - FT.com - Financial Times
3 days ago · Abliva AB (ABLI:STO) company profile with history, revenue, mergers & acquisitions, peer analysis, institutional shareholders and more.See details»
Abliva AB (publ) (STO: ABLI) Company Profile & Overview - Stock …
Nov 1, 2024 · Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden. Company profile for Abliva AB (publ) (STO: ABLI) with a description, list of executives, contact …See details»
Abliva - VentureRadar
Abliva is focused on becoming the leading biopharmaceutical company in mitochondrial medicine, developing therapeutics for primary mitochondrial diseases, orphan indications of high unmet …See details»
Abliva AB Publishes 2022 Annual Report
Mar 31, 2023 · Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today …See details»
Abliva - Products, Competitors, Financials, Employees, …
Abliva focuses on the development of pharmaceuticals within the healthcare sector, specifically targeting mitochondrial diseases. The company's main offerings include the discovery and …See details»
Abliva Company Profile 2024: Stock Performance & Earnings
Abliva AB is a Swedish company that is active in pharmaceutical development. It develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and …See details»
Abliva Company Profile - Office Locations, Competitors, Revenue …
Oct 29, 2024 · Abliva (formerly NeuroVive Pharmaceutical) is a company engaged in the research and development of mitochondrial medicine. Its product portfolio includes NeuroSTAT, a drug …See details»
Abliva AB - Funding, Financials, Valuation & Investors - Crunchbase
Abliva AB is funded by 6 investors. IP Group and Hadean Ventures are the most recent investors. Abliva AB has invested in Isomerase on Aug 15, 2016. in funding over 7 rounds. Their latest …See details»
Annual reports - Abliva
Mar 26, 2018 · Here you'll find all Abliva's annual reports.See details»
NeuroVive Pharmaceutical changes name to Abliva - BioStock
Jul 5, 2021 · As of today, May 29, the company’s share on Nasdaq Stockholm Small Cap will be traded under the ticker ABLI. The name change should be seen as part of the Abliva’s strategy …See details»
Abliva AB publishes 2020 Annual report
Apr 27, 2021 · Abliva AB (Nasdaq Stockholm: ABLI) today announced that the English version of the Annual report for 2020 is now available on the company’s website, www.abliva.com. The …See details»
Abliva AB ESG Risk Rating - Sustainalytics
Abliva AB is a Swedish company that is active in pharmaceutical development. It develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and …See details»